Adding Chemo to Immunotherapy Provides No Benefit in Older NSCLC Patients
Older adults with PD-L1+ NSCLC may fare better if they receive immunotherapy rather than chemoimmunotherapy, data suggest.
Older adults with PD-L1+ NSCLC may fare better if they receive immunotherapy rather than chemoimmunotherapy, data suggest.
Simone Ledward-Boseman has many roles: She’s a writer, artist, and singer. And for some time, she was a caregiver to her late husband, Chadwick Boseman.
This unique NCPD symposium series was designed to assist oncology nurses as they attempt to optimize patient care and interpret recent clinical and research advances.…
Abstract. Novel screening and diagnostic tests based on artificial intelligence (AI) image recognition algorithms are proliferating. Some initial reports c
Investigators have found that the current body of research may inadequately address the intersection of aging, health disparities, and cancer outcomes among older patients.
Please click the link to complete this form.
The FDA has approved nogapendekin alfa inbakicept-pmln plus BCG for BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.
An abstract is unavailable.
Klaus Metzeler, MD, University of Leipzig, Leipzig, Germany, provides insight into the diagnosis and risk stratification of patients with myelodysplastic syndromes (MDS) and outlines some…
Monika Joshi, MD, MRCP, of Penn State Cancer Institute, contextualizes the results of the THOR study within the treatment landscape for FGFR2/3-altered advan…
This randomized clinical trial examines whether adding chemotherapy with pemetrexed and carboplatin to gefitinib improves survival among patients with epidermal growth factor receptor (EGFR)–variant non–small…